Navigation Links
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Date:3/18/2008

CV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks re
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
2. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
9. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
10. Smithfield Foods, Inc. Statement Regarding Animal Cloning
11. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a commercial ... relationship of genetics and hypertension at the International Academy of Cardiology ... Columbia, Canada. The event, which boasts an extensive overview of the latest research ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... ... 2015 , ... PRC Clinical, a Clinical Trial Management Expert CRO, ... in southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based ... , Stem Cell Meeting on the Mesa on October ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... N.Y., Nov. 11 Nikon Instruments Inc. has,provided ... Clemson,University,s College of Agriculture, Forestry and Life Sciences ... The facility will,be the first of its kind ... most,technologically advanced systems Nikon Instruments Inc. has installed,anywhere ...
... --,China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ... pharmaceutical companies in the,People,s Republic of China ("PRC"), ... at 10:00 a.m. EST on Thursday, November 13, ... Hosting the call will be Mr. Colin Zhao, ...
... A1c testing using dried blood spot,specimens, BASKING RIDGE, ... of Hooper Holmes (Amex: HH ), today announced,certification ... Standardization Program (NGSP)., Heritage Labs uses two blood ... specimens and the other for testing dried blood,spots (DBS), ...
Cached Biology Technology:Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility 2Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility 3China Biologic Products Announces Third Quarter 2008 Results Conference Call 2Heritage Labs Announces A1c Test Certification Milestone 2Heritage Labs Announces A1c Test Certification Milestone 3
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... forecasts that predict what the coming winter may ... scientists have developed the first long-term forecast of ... "Being able to predict future phytoplankton blooms, ocean ... said Samantha Siedlecki, a research scientist at the ...
... been shown to increase the pigment in their skin in response ... today in Nature journal, Scientific Reports , reveals that not ... incurring DNA damage in their skin just like us, they also ... older. Experts in the response of skin to UV radiation ...
... University researcher will receive $1.3 million over the next ... Digestive and Kidney Diseases (NIDDK) for research that will ... informing the development of novel treatments to reverse the ... million people worldwide suffer from type 2 diabetes--a number ...
Cached Biology News:New ocean forecast could help predict fish habitat 6 months in advance 2New ocean forecast could help predict fish habitat 6 months in advance 3Whales feel the (sun)burn! 2Whales feel the (sun)burn! 3Type 2 diabetes study to examine role amylin plays in disease 2
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... The JNK (c-Jun NH2-terminal kinase) signal ... identified MAP kinase pathways in mammals. ... to environmental stress, is associated with ... and is implicated in the immune ...
... is an automated, two-dimensional fractionation system for ... Part of Beckman Coulters ProteomeLab family of ... just hours. The system effectively resolves ... lysates, addressing a key challenge in todays ...
... The ProteomeLab PA 800 is ... Part of Beckman Coulters ProteomeLab ... offers a comprehensive range of automated ... determination, peptide mapping, isoelectric focusing, carbohydrate ...
Biology Products: